Novasep to expand HPAPI manufacturing capacity to keep pace with demand

The plan includes the creation of more than 30 full-time jobs at the CDMO's Le Mans site

Having already benefitted from significant investment, Novasep's high potency API manufacturing site at Le Mans, France is set for further expansion to support growing demand.

The CDMO, which has made its mark in the HPAPI and antibody drug conjugates (ADC) space offering integrated development and manufacturing services for both payloads and bioconjugation, says the demand is coming from established collaborations with major pharmaceutical companies and new partnerships with biotechnology innovators.

To support this growth and sustain the increase in both clinical and commercial production capacity, Novasep is recruiting more than 30 people at the Le Mans site, as well as investing more than €4 million.

In 2017, Novasep launched the €12 million bioconjugation facility, which successfully passed an inspection by the ANSM (French regulatory drug authorities) earlier this year.

Last week, Novasep reported strong growth figures for 2020, despite the current health and economic crisis. The company said it completed its Rise-2 strategic plan, which aimed to double profitability, two years ahead of schedule.

In January, Novasep sold its gene therapy and viral vectors business to Thermo Fisher Scientific and announced plans to sell its equipment service line - actions taken by the company to consolidate its market position.